Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model
Vet Comp Oncol, v. 16, n. 4, p. 478-488, dez. 2018
Article
em En
| SES-SP, SESSP-IBPROD, SES-SP
| ID: bud-2607
Biblioteca responsável:
BR78.1
ABSTRACT
Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The ther-apeutic protocols adopted for dogs and humans are very similar, involving surgical options suchas amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. How-ever, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treat-ments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined withrecombinant human bone morphogenetic protein (rhBMP-2) may be associated with decreasesof the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy ofchemotherapy with carboplatin and rhBMP-2 with MSCs in a canine OSA in vivo model. CanineOSA cells were implanted in mice Balb-c/nude with MSCs, rhBMP-2 and carboplatin. Flow cyto-metry and PCR for markers involved in tumour suppression pathways were analysed. Resultsshowed that the combination of MSCs and rhBMP-2 reduced tumour mass and infiltration ofneoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated thatthe use of rhBMP-2 and MSCs, in combination with conventional antineoplastic, may be an effi-cient treatment strategy.
Texto completo:
1
Coleções:
06-national
/
BR
Base de dados:
SES-SP
/
SESSP-IBPROD
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Vet Comp Oncol
Ano de publicação:
2018
Tipo de documento:
Article